Project 416989

There is a need to examine the impact and importance of sex, gender and equity in the life cycle management of prescription drugs to support compliance with contemporary practices in developing standards and policies, and to inform more precise medicine and health care. Greaves will partner with policy leads at Health Canada, Health Products and Food Branch (HPFB) to apply a SGBA+ lens to prescription drug lifecycle management. Greaves is Senior Investigator at the Centre of Excellence for Women's Health (CEWH), an organization with a strong 22 year record in sex and gender based analyses, critical social research methods and knowledge translation. Greaves will support the policy partner in: assessing the inclusion of sex, gender and equity in Health Canada regulatory decision-making; assessing industry compliance with Health Canada's policy on the inclusion of females in clinical trials; developing recommendations for the improvements in guidance for industry; and developing recommendations for improving knowledge translation on sex differences in drug safety and/or efficacy. Greaves will apply her deep and varied experience in SGBA+, and consult with experts in pharmacology, advocacy, and knowledge transfer (Eltonsy, Boscoe), who are members of the Scientific Advisory Committee on Health Products for Women of which Greaves is the appointed chair. In addition, she will draw on the research capacity of the CEWH and consult with the Director of the CEWH (Poole), a knowledge translation expert with experience in research and education on sex and gender issues related to drugs. Greaves' extensive experience in sex and gender science in health research, and designing and delivering SGBA training, resources and tools will support the policy partner to both apply SGBA+ to prescription drug lifecycle management and also to build ongoing capacity.